8[1]Hortobagyi GN,Theriault RL,Lipton A,et al.Longerm prevention of skeletal complications of metastatic breast cancer with pamidronate.J Clin Oncol,1998,16:2038
9[2]Theriault RL,Lipton A,Hortobagyi GN,et al.Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:A randomized,placebo-controlled trial.Protocol 18 Aredia Breast Cancer Study Group.J Clin Oncol,1999,17:846
10[3]Conte PF,Latreille J,Mauriac L,et al.Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate:Results from a multinational randomized controlled trial.J Clin Oncol,1996,14:2552
1Morgan G,Lipton A. c Antitumor effects and anticancer applications of bisphosphonates[J].Seminars in Oncology,2010,(Suppl 2):S30-S40.
2Coleman R,Cook R,Hirsh V. Zoledronic acid use in cancer patients:more than just supportive care[J].Cancer,2011,(01):11-23.
3Ignatoski KM,Friedman J,Escara-Wilke J. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer:interleukin-6 response is a potential carly indicator of response to therapy[J].J nterferon Cytokine Res,2009,(02):105-112.
4Tumminello FM,Badalamenti G,ncorvaia L. Serum interleukin-6 in patients with metastatic bone disease:correlation with cystatin C[J].Medical Oncology,2009,(01):10-15.
5Kimachi K,Kajiya H,Nakayama S. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogeneais[J].Naunyn Schriedebergs Arch Pharmacol,2011,(03):297-308.
6Leto G,Badalamenti G,Arcara C. Effects of zoledronic acid on proteinase plasrma levels in patients with bone metastases[J].Anticancer Research,2006,(1A):23-26.
7Hatoum HT,Lin SJ,Smith MR. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis[J].Clinical Breast Cancer,2011,(03):177-183.
